Delivering a substance intravenously means sending it directly into the bloodstream through a vein, and that single difference from swallowing a pill changes almost everything about how a drug behaves in your body. The effect is faster, the dose can be smaller, and the control over how much drug reaches your tissues is far more precise. But the tradeoffs are real: intravenous therapy requires puncturing a vein, introduces infection risk, and demands monitoring that an oral pill does not. Understanding what happens when something enters your bloodstream this way, what can go wrong, and how modern medicine manages those risks helps make sense of why IV delivery remains essential in hospitals even as science keeps looking for alternatives.
Why Bypassing the Gut Changes Everything
When you swallow a medication, it has to survive your stomach acid, get absorbed through the intestinal wall, and then pass through the liver before reaching the rest of your body. The liver is especially important here because it can break down a large portion of the drug on this first pass. This process, known as first-pass metabolism, means that for some drugs, much larger oral doses are needed to achieve the same blood levels you would get from a small intravenous dose.1PubMed. First-pass elimination. Basic concepts and clinical consequences Morphine is a classic example: the oral dose is roughly three times the IV dose because the liver chews through so much of it before it ever circulates.
Intravenous delivery sidesteps all of that. The drug enters the bloodstream at full strength, which is why an IV dose is often the reference point against which other routes are measured. When researchers talk about a drug’s “bioavailability,” they are comparing how much of the drug reaches the bloodstream by one route versus the amount that gets there intravenously, which is, by definition, 100 percent.
Bolus Versus Continuous Infusion
Not all IV delivery is the same. A bolus injection pushes a full dose into the vein over seconds to minutes, while a continuous infusion drips the drug slowly over hours or even days. The choice between the two is not arbitrary; it changes peak drug concentrations and how long the drug stays active.
Research on the chemotherapy drug doxorubicin illustrates the gap clearly. In one study, peak blood levels after a bolus injection were roughly 17 times higher than after a slow infusion of the same total dose, even though the overall drug exposure measured over time was similar.2PubMed. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit In patients with chronic lymphocytic leukemia, bolus doxorubicin produced peak blood levels more than 100 times higher than continuous infusion, and the amount of drug that actually got inside cancer cells was nearly three times greater after a bolus.3PubMed. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion That matters because higher intracellular drug levels can mean better tumor killing, but they can also mean more side effects. The decision about which approach to use depends on what the drug does, how toxic it is at high peaks, and what the treatment goals are.
Getting Access to a Vein
Before anything can be infused, a catheter has to get into a blood vessel, and the type of catheter chosen depends on what is being given, how long the therapy will last, and how sick the patient is.
- Peripheral IV: The short catheter placed in a hand or forearm vein. It is the most common type, quick to insert, and suitable for most short-term treatments, but it is also the most prone to failure.
- Central venous catheter: A longer line threaded into one of the large veins near the heart, used when drugs are too concentrated or caustic for small veins, or when access is needed for weeks.
- PICC line: A peripherally inserted central catheter, placed through an arm vein but advanced until its tip sits near the heart. It bridges the gap between a peripheral IV and a surgically placed central line, often used for home IV antibiotic courses.
- Intraosseous access: A needle drilled into the bone marrow, most often in the shin. This route is used in emergencies when veins have collapsed or cannot be found quickly enough.
Peripheral IVs dominate hospital settings, but their track record is surprisingly rough. A large meta-analysis found that roughly one in three peripheral IVs fails before treatment is finished, at a rate of about four to five failures per 100 catheter-days.4PubMed. Peripheral intravenous catheter infection and failure: A systematic review and meta-analysis Failure does not always mean infection; it often means the catheter clogs, slips out, or the surrounding tissue swells from fluid leaking outside the vein. Still, the sheer frequency means nurses and patients deal with restarts constantly.
How Long Should a Peripheral IV Stay In?
Hospitals have traditionally replaced peripheral IVs every 72 to 96 hours as a precaution against infection. The evidence behind that routine is more nuanced than it appears. One early study found that the difference in failure rates between a catheter left in for six days versus replacing it at three days was only about one percent.5PubMed. Relationship between peripheral intravenous catheter Dwell time and the development of phlebitis and infiltration That modest gap has fueled ongoing debate about whether routine replacement schedules are necessary at all, or whether a “replace when clinically indicated” approach works just as well.
However, a 2025 study looking specifically at bloodstream infections painted a more cautious picture. The risk of a bloodstream infection was low during the first two days but jumped sharply after three days of catheter dwell time, with the adjusted odds roughly 13 times higher compared to a freshly placed line.6JAMA Network Open. Dwell Time and Risk of Bloodstream Infection With Peripheral Intravenous Catheters The risk stayed elevated for as long as the catheter remained. So while phlebitis and minor complications may not increase dramatically with a few extra days, the bloodstream infection risk climbs meaningfully, which keeps the debate alive among infection-control specialists.
When Veins Are Not an Option
In trauma and cardiac arrest, the usual IV approach can fail spectacularly. Collapsed veins, severe blood loss, and chaotic emergency settings make it hard to thread a catheter into a peripheral or even a central vein. Intraosseous access, where a needle is drilled into the bone marrow, has become the go-to backup. The marrow contains a rich network of sinusoidal vessels that drain into the central circulation, so fluids and drugs injected there reach the heart quickly.
Studies comparing the two routes in trauma patients found that intraosseous access succeeded on about 93 to 95 percent of attempts, compared with roughly 42 to 67 percent for peripheral IV and 46 to 59 percent for central venous access.7BMJ. Intraosseous access in the resuscitation of patients with trauma: the good, the bad, the future Placement times were similar for intraosseous and peripheral IV, both generally under a minute, but the higher success rate meant patients actually started receiving treatment faster with the bone route. An earlier comparison in a controlled setting found that emergency drugs delivered through bone marrow produced peak effects and drug levels comparable to both central and peripheral intravenous routes.8American Journal of Diseases of Children. Comparison Study of Intraosseous, Central Intravenous, and Peripheral Intravenous Infusions of Emergency Drugs In adult emergency departments, a pilot study showed intraosseous placement averaged about two minutes versus nearly ten minutes for a central line, with a 90 percent first-attempt success rate for intraosseous versus 60 percent for central venous access.9PubMed Central. Is the intraosseous access route fast and efficacious compared to conventional central venous catheterization in adult patients under resuscitation in the emergency department? A prospective observational pilot study
Complications of Intravenous Therapy
Any time a needle breaks the skin and enters a blood vessel, a set of risks comes along. The most common complication for peripheral IVs is phlebitis, an inflammation of the vein wall that causes pain, redness, and swelling along the catheter site. In one study of over 1,300 adults, about six percent developed phlebitis, with risk factors including reduced mobility, catheter placement on the back of the hand, and certain drugs like amoxicillin-clavulanate.10PubMed Central. Risk factors for peripheral intravenous catheter-related phlebitis in adult patients Another study linked catheter dwell times beyond 72 hours and forearm puncture to higher rates of phlebitis, and flagged specific antibiotics, including ceftriaxone, clarithromycin, and oxacillin, as contributors.11PubMed Central. Incidence of phlebitis associated with the use of peripheral IV catheter and following catheter removal In children, the risk factors shift somewhat: catheters placed in the lower limbs, novice inserters, and contaminated dressings drove higher phlebitis rates in a pediatric population.12PubMed. The Incidence of Peripheral Intravenous Catheter Phlebitis and Risk Factors among Pediatric Patients
Central lines carry a different risk profile. Because they sit in large central veins and stay in place for weeks or longer, their main threat is catheter-related bloodstream infection. PICC lines, for instance, showed infection in about three percent of patients in one retrospective study, with thrombosis (blood clots forming around the catheter) occurring at a similar rate.13PLOS ONE. Complications of Peripherally Inserted Central Venous Catheters: A Retrospective Cohort Study
Extravasation is another concern, particularly with chemotherapy. When a vesicant drug leaks out of the vein and into surrounding tissue, it can cause tissue death, permanent scarring, and loss of function if not caught quickly.14PubMed Central. Extravasation of antineoplastic agents: prevention and treatments This is one reason many chemotherapy regimens call for a central line rather than a peripheral IV.
Air embolism is rare but potentially fatal. When a large volume of air enters the venous system, it can block blood flow through the heart or lungs. Case reports have documented fatal air embolism following ordinary intravenous infusions, though the amount of air required to cause serious harm is much larger than the small bubbles patients sometimes worry about seeing in their tubing.15PubMed. Fatal venous air embolism following intravenous infusion
Infection Prevention Bundles
Central-line-associated bloodstream infections were once considered an unavoidable cost of intensive care. Over the past two decades, hospitals have dramatically reduced them using standardized “bundles,” checklists of evidence-based practices applied consistently during catheter insertion and maintenance. A systematic review and meta-analysis found that implementing these bundles cut infection rates from a median of about six per 1,000 catheter-days down to about two and a half.16The Lancet Infectious Diseases. Effectiveness of prevention (insertion and maintenance) bundles for catheter-associated bloodstream infections in intensive care units: a systematic review and meta-analysis One hospital’s nine-year observation showed even more dramatic improvement, dropping from 2.6 to 0.46 infections per 1,000 catheter-days after adopting chlorhexidine-impregnated dressings, structured training, and real-time monitoring.17PubMed Central. The Effectiveness of Bundle Applications in the Prevention of Central Line-associated Bloodstream Infections: Nine Years of Observation A coronary ICU achieved zero infections by combining standardized insertion kits, simulation-based training, and direct observation of compliance.18PubMed Central. Bundle approach used to achieve zero central line-associated bloodstream infections in an adult coronary intensive care unit
The lesson from this body of work is that most central-line infections are preventable. The challenge is sustaining compliance. Bundles work only when every step is followed every time, and human factors like fatigue, time pressure, and turnover create persistent gaps.
IV Fluids in Critical Care
Intravenous fluids are among the most commonly administered substances in hospitals, and the choice between crystalloids (saltwater-based solutions like normal saline and Ringer’s lactate) and colloids (solutions containing larger molecules like albumin or starches) has been debated for decades. A Cochrane systematic review covering thousands of critically ill patients concluded that using colloids instead of crystalloids probably makes little or no difference to mortality.19PubMed Central. Colloids versus crystalloids for fluid resuscitation in critically ill patients Starch-based colloids did carry a catch: they slightly increased the need for blood transfusions and kidney-replacement therapy.20Cochrane Database of Systematic Reviews. Colloids versus crystalloids for fluid resuscitation in critically ill people
Too much IV fluid is itself a problem. In patients with severe heart failure and cardiogenic shock, those who were fluid-overloaded at ICU discharge had a 30-day death rate roughly double that of patients who were not, though after statistical adjustment the difference was less clear-cut.21Frontiers in Medicine. Fluid overload and mortality in critically ill patients with severe heart failure and cardiogenic shock–An observational cohort study The takeaway is that IV fluids are not inherently benign. Getting the right amount into the right patient matters as much as getting the right drug.
Time-Sensitive IV Treatments
Some intravenous therapies are defined by the clock. Stroke treatment with IV clot-dissolving medication is the most dramatic example. Randomized trials have long supported using IV tissue-type plasminogen activator within three hours of stroke onset, and more recent evidence has extended the treatment window to four and a half hours for selected patients.22PubMed Central. Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset
Pushing even further, a meta-analysis of 14 randomized trials including over 4,000 patients found that IV clot-busting drugs given beyond 4.5 hours still improved functional outcomes compared with standard care. About one additional patient achieved a good recovery for every 12 to 16 treated. The tradeoff was a higher risk of bleeding in the brain, with about one extra bleeding event for every 62 patients treated, and no clear difference in death rates.23JAMA Network Open. Intravenous Thrombolysis Beyond the Conventional Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis These numbers capture the essence of many IV treatments: powerful effects that come with real risks, making patient selection and timing critical.
Parenteral Nutrition
When a person cannot eat or absorb food through the gut, all of their calories, protein, fat, vitamins, and minerals can be delivered intravenously as parenteral nutrition. The solutions are highly concentrated, which is why they usually require a central line rather than a peripheral IV. Peripheral parenteral nutrition does exist, but it delivers fewer calories in a larger volume and is limited to short-term use.24PubMed Central. Parenteral Nutrition Overview
Parenteral nutrition is expensive and carries its own complications, including high blood sugar, elevated blood fats, electrolyte imbalances, and infections linked to the venous access line. Careful monitoring of blood work throughout treatment is essential to catch and correct imbalances early. The goal is always to transition the patient back to eating whenever the gut recovers, because the intestine itself benefits from having nutrients pass through it.
IV Therapy at Home
Intravenous therapy is no longer confined to hospitals. Outpatient parenteral antimicrobial therapy, known as OPAT, allows patients to receive IV antibiotics at home, often through a PICC line, for infections that require weeks of treatment. A systematic review and meta-analysis of randomized trials found that OPAT is a safe and effective alternative to staying in the hospital for the full course.25PubMed. Safety and efficacy of outpatient parenteral antimicrobial therapy: A systematic review and meta-analysis of randomized clinical trials
Concerns about whether patients with substance use histories can safely manage their own IV lines at home have also been studied. A program at an urban safety-net hospital found that completion rates were statistically indistinguishable: about 91 percent of patients with a drug or alcohol history completed their OPAT course, compared with 89 percent of patients without such a history.26Open Forum Infectious Diseases. Home-Based Outpatient Parenteral Antibiotic Therapy at an Urban Safety Net Hospital: Comparing Outcomes in Persons With and Without Noninjection Drug Use These findings have pushed many infectious-disease programs to expand home IV access rather than keeping patients hospitalized for weeks, cutting costs and improving quality of life. A study of patients with spinal infections found that those on home OPAT averaged about 41 days of treatment after discharge, with no PICC line complications or adverse lab findings detected.27PubMed Central. Safety and feasibility of outpatient parenteral antimicrobial therapy for patients with spinal infection
Smart Pumps and Dosing Safety
One of the more consequential innovations in IV therapy has been the smart infusion pump. These devices contain drug libraries with pre-programmed dose limits, alerting nurses if a programmed rate falls outside safe boundaries. A scope review found that smart pumps decrease errors related to incorrect rate and dose.28PubMed Central. The Impact of Smart Pump Technology in the Healthcare System: A Scope Review At an Australian teaching hospital, the introduction of smart pumps with dose-checking software cut the proportion of infusions with at least one error from 18 percent to under four percent, and virtually eliminated errors classified as having extreme or high clinical significance.29Journal of Pharmacy Practice and Research. Smart infusion pumps reduce intravenous medication administration errors at an Australian teaching hospital
Newer systems go further by integrating pumps with electronic health records, so that a physician’s order flows directly into the pump without manual re-entry. A systematic review found that this interoperability reduced specific medication errors by 15 to 55 percent, and overall medication errors dropped by 21 to 90 percent depending on the setting.30PubMed Central. Evaluating the Impact of Smart Infusion Pump Interoperability on Reducing Medication Administration Errors: A Systematic Literature Review The wide range reflects how much baseline error rates varied across hospitals before implementation. The technology is not a cure-all: alert fatigue, where clinicians override so many soft warnings that they stop paying attention, remains a persistent problem, as do delays in keeping drug libraries up to date.
Neonatal and Pediatric Challenges
Intravenous therapy in newborns and young children comes with its own difficulties. Veins are tiny, skin is fragile, and a baby cannot tell you that something hurts until it is already a problem. In neonates, peripheral IVs have strikingly short lifespans. One study found that the average dwell time for peripheral venous catheters in newborns was roughly 37 to 43 hours, far shorter than in adults.31Wolters Kluwer — Medknow Publications. Complication and Dwell Time of Neonatal Peripheral Venous Catheters with and without Splint: A Descriptive, Correlational, and Prospective Study Extravasation, where fluid leaks out of the vein into surrounding tissue, was the most common complication in neonates whose IVs were stabilized with splints, occurring in over half of catheterizations. Splints did extend dwell time modestly, but the complication rates remained high regardless.
Fear and pain around needle procedures are also amplified in children. Research shows that a child’s fear and pain during needle procedures are tightly intertwined, with fear accounting for a substantial portion of the variation in pain reports and vice versa.32PubMed. The relationship between fear and pain levels during needle procedures in children from the parents’ perspective Parental anxiety feeds into the cycle too, with the parents’ own fear levels predicting their child’s pain. Pediatric units increasingly use topical anesthetics, distraction techniques, and child life specialists to break this feedback loop before the needle is even unwrapped.
A Brief History of Getting Fluids Into Veins
The idea of injecting substances into a vein dates back to the 1600s, but early attempts were crude and often deadly. Modern IV therapy as a practical medical tool is less than a century old.33PubMed. The history of intravenous therapy The two World Wars were the main catalysts, as battlefield medicine demanded ways to replace lost blood and fluids quickly. Disposable plastic tubing, manufactured sterile solutions, and the butterfly needle all emerged in the mid-twentieth century. The biggest leaps in drug delivery, equipment, and infection control have come since the 1970s, driven by the expansion of ICU care, chemotherapy, and later by the HIV epidemic, which forced a complete rethinking of how healthcare workers handle needles and bodily fluids. What started as a desperate wartime measure has become so routine that an estimated 80 percent or more of hospitalized patients receive some form of IV therapy during their stay.